Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

    (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

  • (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLxU5BKSzVyPUWuPFY3PiEQvF2= M2DndXNCVkeHUh?=
DOHH-2 NVKyPFVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T2[2lEPTB;OT6zOVY5QSEQvF2= M{nNNnNCVkeHUh?=
no-10 NHe4PW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfhSol2UUN3ME25MlkxOzlizszN MlPNV2FPT0WU
LS-513 NIXKXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFzLkO1OFch|ryP MWLTRW5ITVJ?
ALL-PO NYjuS451T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorDTWM2OD1zMT63O|M1KM7:TR?= NWPHdJFFW0GQR1XS
8-MG-BA NF3JcJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPGZ|ZKSzVyPUGzMlEyOjNizszN NEnZTJBUSU6JRWK=
RPMI-8402 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3TTWM2OD1zNT64OVM4KM7:TR?= M1vS[3NCVkeHUh?=
EoL-1-cell NFLhfFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILCe5VKSzVyPUG4MlU6PDhizszN NIWzVpRUSU6JRWK=
NALM-6 MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnKNoNYUUN3ME2xPU4xOTZ5IN88US=> MWnTRW5ITVJ?
DEL MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljhTWM2OD1{MD6xOFcyKM7:TR?= MorlV2FPT0WU
SR NETTfXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf2WmlYUUN3ME2yN{43PzF3IN88US=> NIDyVGxUSU6JRWK=
697 NEfYTotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[3TYhLUUN3ME2yOk43OTV3IN88US=> MkXWV2FPT0WU
COLO-829 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml61TWM2OD1{Nj64OFg{KM7:TR?= M1HGOHNCVkeHUh?=
EVSA-T MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnYUo9KSzVyPUK3MlU2PjFizszN MY\TRW5ITVJ?
ATN-1 M3POUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu3TWM2OD1|MT6yN|I6KM7:TR?= NGH2R|ZUSU6JRWK=
L-363 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\5V2lEPTB;M{GuO|Q3OSEQvF2= NI[0XG1USU6JRWK=
LAMA-84 MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzVUXRKSzVyPUOyMlUzOTFizszN NVjqfpM{W0GQR1XS
NOS-1 NVq4TJZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEm5fVlKSzVyPUO0MlI6PTZizszN MlLWV2FPT0WU
BB30-HNC NET3PZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTN2LkOzNFYh|ryP NU\yNm05W0GQR1XS
BC-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[3fGlEPTB;M{euPVc1PiEQvF2= NVHnd|NHW0GQR1XS
IST-SL2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTN6LkKyOEDPxE1? M{fKfXNCVkeHUh?=
D-392MG NWL0TZZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjRTWM2OD12MD6yNlE2KM7:TR?= MWrTRW5ITVJ?
no-11 M4C1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Tpb2lEPTB;NECuOVUzOSEQvF2= MYXTRW5ITVJ?
LC4-1 NF\MfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\mVFJ3UUN3ME20NE45PzF4IN88US=> MX\TRW5ITVJ?
A388 MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PUW2lEPTB;NEKuOVg1QCEQvF2= Ml;UV2FPT0WU
NTERA-S-cl-D1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;XTWM2OD12Mj63NFc1KM7:TR?= MonuV2FPT0WU
CESS M3ToTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LVVmlEPTB;NESuNlI{OiEQvF2= NF\KXGNUSU6JRWK=
RS4-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7BNlZHUUN3ME20PU4xQTN6IN88US=> MlzKV2FPT0WU
MS-1 NEjzN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTVyLkmzOVEh|ryP MlG3V2FPT0WU
CTV-1 M2n4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL4TWM2OD13MT6wO|Qh|ryP MkG0V2FPT0WU
D-502MG NWrwTXdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTVzLk[yO|Eh|ryP NFTwNXdUSU6JRWK=
ML-2 MkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFKxVXBKSzVyPUWyMlkyQTVizszN NYn5VmFPW0GQR1XS
SK-NEP-1 Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;BfmdKSzVyPUWzMlM6OjNizszN NVHVTVBQW0GQR1XS
LOXIMVI MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3znSGlEPTB;NUOuOVg5PCEQvF2= M2nXdnNCVkeHUh?=
DJM-1 M3XvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP5TWM2OD13Nj6zN|kyKM7:TR?= MnrSV2FPT0WU
GI-1 M{ToTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETXPHlKSzVyPUW2MlYyPDlizszN MWPTRW5ITVJ?
IST-MES1 MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfyTWM2OD14MD61OFk{KM7:TR?= NUP2WJpkW0GQR1XS
MV-4-11 M3PmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLwXY1KSzVyPU[wMlY2OzhizszN NFL0eXNUSU6JRWK=
OVCAR-4 M1K3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTZ|LkW2OVch|ryP NVfWVGtMW0GQR1XS
KE-37 NGHmTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHCdoJoUUN3ME22Ok4zPjZ6IN88US=> NGrycldUSU6JRWK=
D-542MG M2TkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLQTWM2OD14OD60NVM2KM7:TR?= M1zmcXNCVkeHUh?=
MHH-PREB-1 NYDKd2JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\yTWM2OD15Mj64OFQyKM7:TR?= NXyxVYFoW0GQR1XS
MRK-nu-1 MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrtTWM2OD15Mz60O|A2KM7:TR?= NXzQcnZ2W0GQR1XS
D-247MG NUToPZg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj3R4RSUUN3ME23N{42PDR{IN88US=> MkPMV2FPT0WU
OCI-AML2 NXnwPGZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DJbmlEPTB;N{[uPVM3QSEQvF2= M17VfXNCVkeHUh?=
LP-1 NI[yeYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XEdWlEPTB;OEKuPFc{OSEQvF2= M4PQWXNCVkeHUh?=
HCC1599 NWLu[JU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LMcGlEPTB;OESuNlg{PyEQvF2= Ml64V2FPT0WU
KARPAS-45 MmnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvoTWM2OD16ND62PVkzKM7:TR?= NU\6SFROW0GQR1XS
BE-13 NYXnWZRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTBTWM2OD17OT6wOFc4KM7:TR?= Mm\6V2FPT0WU
GCIY NYXMfYNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXDbmNKSzVyPUm5MlA6PTRizszN MoC1V2FPT0WU
BV-173 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;nV4lKSzVyPUGwNE4{OjVizszN NVjoVWZ{W0GQR1XS
LB2518-MEL NHTZe5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7OSZpKSzVyPUGwNE44QDlizszN NVHqe4M6W0GQR1XS
KS-1 Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFyMT62N|kh|ryP NIHQ[3ZUSU6JRWK=
MOLT-16 M3yzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFyND65PFYh|ryP NGXSXIVUSU6JRWK=
NCI-H1770 M1KwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDMc|BCUUN3ME2xNFgvPzh2IN88US=> NFPyeplUSU6JRWK=
NCI-H82 M3L6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7DVolOUUN3ME2xNVAvQTd4IN88US=> MYTTRW5ITVJ?
NCCIT NGjjNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH1ZlBoUUN3ME2xNVIvPTJ7IN88US=> MYjTRW5ITVJ?
KALS-1 NWXCc4hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7qTWM2OD1zMUWuPVQyKM7:TR?= NXfqfnppW0GQR1XS
LB2241-RCC NIDzdlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPuXFlwUUN3ME2xNVYvPjd7IN88US=> NXfUWZFyW0GQR1XS
HH NWjCSWtWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFzNz6zPVUh|ryP MV\TRW5ITVJ?
HD-MY-Z MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3OTWM2OD1zMUiuOFg5KM7:TR?= NH3WZXdUSU6JRWK=
EB-3 M{foTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETyTVVKSzVyPUGyN{4xQTRizszN NIHHWYNUSU6JRWK=
BL-70 M1fldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTF{Mz6xNlch|ryP M2Lo[XNCVkeHUh?=
K-562 M2WwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K1dmlEPTB;MUK2MlI1PSEQvF2= MoThV2FPT0WU
HT-144 M4DlNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjFTWM2OD1zM{OuNVY1KM7:TR?= MkHNV2FPT0WU
PF-382 NGK5fFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DRNGlEPTB;MUO0MlM3OSEQvF2= MkHvV2FPT0WU
RPMI-8226 NXz5cpZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LINWlEPTB;MUO1MlA1PSEQvF2= NEPRWmtUSU6JRWK=
NCI-H1355 MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTF|NT61PFch|ryP NYXn[4VlW0GQR1XS
LXF-289 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXKTWM2OD1zM{muO|gyKM7:TR?= MWnTRW5ITVJ?
NCI-H69 MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnmwTWM2OD1zNEKuPVMzKM7:TR?= NUjQbpozW0GQR1XS
SK-MEL-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XPSmlEPTB;MUS3MlE{KM7:TR?= Mn7JV2FPT0WU
KARPAS-299 NVWxcmdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF2OT6xNkDPxE1? MWLTRW5ITVJ?
GB-1 Mk\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPDN|dGUUN3ME2xOFkvOzJ{IN88US=> NF75fFVUSU6JRWK=
CMK MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC0XVRjUUN3ME2xOFkvPTF3IN88US=> M4LDU3NCVkeHUh?=
MPP-89 Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPJW2tKSzVyPUG1Ok4xOzVizszN M4G2c3NCVkeHUh?=
KU812 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PrXmlEPTB;MU[xMlkxOiEQvF2= NH3OSXFUSU6JRWK=
REH MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrVcJQxUUN3ME2xOlIvOTJ3IN88US=> M1nsTXNCVkeHUh?=
NEC8 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\JTWM2OD1zNkWuNFI3KM7:TR?= NFvnT21USU6JRWK=
KP-N-YS M3ywfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljNTWM2OD1zNkiuN|k2KM7:TR?= MXnTRW5ITVJ?
Ramos-2G6-4C10 NF\NSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfMfY9JUUN3ME2xOlkvQTF3IN88US=> MWHTRW5ITVJ?
Becker MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFy3WW5KSzVyPUG3OE4yQCEQvF2= MlPyV2FPT0WU
LB647-SCLC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXWe21KSzVyPUG3OU45PDVizszN MkiwV2FPT0WU
LU-139 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXXR|JKSzVyPUG3PE4xOTlizszN NXi3VFRyW0GQR1XS
QIMR-WIL NWTjRYxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\hTGlEPTB;MUe5MlY1PiEQvF2= NVTGUWNGW0GQR1XS
NCI-H1395 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvZdo9KSzVyPUG3PU46QTZizszN MoHPV2FPT0WU
NOMO-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfST5NKSzVyPUG4Nk45PSEQvF2= MYrTRW5ITVJ?
GI-ME-N NXfFNYQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mon6TWM2OD1zOEeuPVY6KM7:TR?= MUTTRW5ITVJ?
KMS-12-PE NYjrcHVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrMdXNKSzVyPUG4PU4zPzNizszN NHXTfnJUSU6JRWK=
Daudi M17H[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\3[nNQUUN3ME2xPVEvOTJ6IN88US=> MVfTRW5ITVJ?
LB996-RCC M3HXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTGeVdrUUN3ME2xPVEvPjl7IN88US=> MnPRV2FPT0WU
NCI-H2107 NHXMUGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXnVYhKSzVyPUG5N{44OzlizszN MlnyV2FPT0WU
SK-PN-DW MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LmW2lEPTB;MUm0MlcyQSEQvF2= MnXmV2FPT0WU
MC-CAR M2TQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJyMj6yOVMh|ryP MWTTRW5ITVJ?
SNB75 MnHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXqN2RKSzVyPUKyNU46PCEQvF2= NFriSldUSU6JRWK=
ES4 NUXMV5R[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnITWM2OD1{MkOuO|g{KM7:TR?= MWrTRW5ITVJ?
KARPAS-422 M4HK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;vOGlEPTB;MkK4MlM2OiEQvF2= NX\GUHJCW0GQR1XS
NCI-H1648 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDjNXZbUUN3ME2yNlkvPDh7IN88US=> MX7TRW5ITVJ?
ES6 NFXkb49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7UTWM2OD1{M{muOFMh|ryP M1jrRnNCVkeHUh?=
KNS-81-FD Mlu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJ2MT6xPVch|ryP NWTOTpI1W0GQR1XS
JAR NV;XTmN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;nTWM2OD1{NU[uNlI2KM7:TR?= M4fsd3NCVkeHUh?=
NB1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TOOGlEPTB;Mk[wMlUyPiEQvF2= NWDlNY5JW0GQR1XS
D-336MG M1zvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrWTWM2OD1{NkCuOlk5KM7:TR?= MkLaV2FPT0WU
BC-3 MlnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHNTWM2OD1{NkWuNVc5KM7:TR?= MmXhV2FPT0WU
HCC2218 MnXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\vVpZKSzVyPUK2Ok41OTVizszN NW\Obpp4W0GQR1XS
TE-9 M3XhOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXHTWM2OD1{Nk[uOlI4KM7:TR?= MnPCV2FPT0WU
LB1047-RCC NEHlcXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3u2T2lEPTB;Mk[2Mlc2OyEQvF2= NEXMeXhUSU6JRWK=
CTB-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4GxT2lEPTB;Mk[5Mlk4OyEQvF2= NFHiRlJUSU6JRWK=
NB7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3BSnVxUUN3ME2yO|Eh|ryP NWLON5IzW0GQR1XS
ST486 NEjoRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HzbWlEPTB;Mke3MlQyOiEQvF2= NXTJWI44W0GQR1XS
HCC1187 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ6Mj64NVEh|ryP NGfUdWpUSU6JRWK=
NCI-SNU-16 NYfnSYdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnqPXlPUUN3ME2yPFQvOjR6IN88US=> M{XUNHNCVkeHUh?=
COR-L279 NG\EenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnVNHFKSzVyPUK5NU42QDRizszN M{jzWXNCVkeHUh?=
ES8 M4LaSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfNRXpKSzVyPUK5OE4yQDJizszN NG\rZXRUSU6JRWK=
U-698-M MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2flXWlEPTB;Mkm4MlI1OyEQvF2= Mm[4V2FPT0WU
HEL NYf1fGJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTNyOT6xOFkh|ryP NVTTT4NSW0GQR1XS
KINGS-1 NUmwb2NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDpb5lbUUN3ME2zNVAvPjd2IN88US=> MUPTRW5ITVJ?
KY821 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX2RVd3UUN3ME2zN|YvPTl3IN88US=> MlvvV2FPT0WU
MZ1-PC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHWzOmZKSzVyPUO0OU43OThizszN MnvwV2FPT0WU
LS-411N M1jFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzXdm1KSzVyPUO1OE43PiEQvF2= MVrTRW5ITVJ?
SIG-M5 MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj5TWM2OD1|NUmuO|gzKM7:TR?= MXfTRW5ITVJ?
HT NVzJN3M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfhTWM2OD1|NkeuO|EyKM7:TR?= NG\uTJpUSU6JRWK=
HC-1 NUXifZNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fXeGlEPTB;M{[3Mlc5PyEQvF2= Mn3CV2FPT0WU
NCI-H1694 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvWTZpKSzVyPUO3Nk46OzRizszN M1zOb3NCVkeHUh?=
BB65-RCC NEi4XoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnHe5FxUUN3ME2zO|YvOjR3IN88US=> MnvXV2FPT0WU
HAL-01 NFTJ[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fpTmlEPTB;M{e5Mlg{QCEQvF2= NHm2PVRUSU6JRWK=
ARH-77 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTN7ND6wNFgh|ryP M1GwUHNCVkeHUh?=
MZ7-mel MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHXUJk3UUN3ME2zPVcvOjN|IN88US=> M3jFbHNCVkeHUh?=
SIMA NGrFc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITqZYNKSzVyPUSwN{46OzNizszN MnWzV2FPT0WU
DG-75 MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TZbWlEPTB;NEG1MlY6QCEQvF2= NHG4cXlUSU6JRWK=
HUTU-80 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIGxSm9KSzVyPUSxPU4yQDVizszN MoG5V2FPT0WU
KNS-42 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm3WItKSzVyPUSyOU45OTVizszN M2rodnNCVkeHUh?=
SH-4 MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHpWJlTUUN3ME20NlcvPTZ3IN88US=> MkDuV2FPT0WU
L-540 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Xvc2lEPTB;NEOxMlA{OSEQvF2= M1v2UnNCVkeHUh?=
NB10 Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7mTWM2OD12NEGuNlM1KM7:TR?= MoG2V2FPT0WU
ES1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fsTGlEPTB;NEWyMlc2OyEQvF2= M2DKc3NCVkeHUh?=
KMOE-2 M2nMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn2TWM2OD12NU[uO|EyKM7:TR?= NWH4eXNCW0GQR1XS
MC116 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYGxc5VVUUN3ME20OVgvOTF4IN88US=> NUTPNHVbW0GQR1XS
RCC10RGB M{T5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfSTWM2OD12NkCuNFA2KM7:TR?= NFHLUYdUSU6JRWK=
RL95-2 NHHOcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTR4MD6yN|ch|ryP NEXVT5NUSU6JRWK=
Raji NGHSe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPxTWM2OD12NkiuNVQ{KM7:TR?= M2XqZ3NCVkeHUh?=
CAS-1 MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zlWWlEPTB;NEeyMlA4OyEQvF2= NEX5UGtUSU6JRWK=
Calu-6 MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnqTWM2OD12N{WuNlY2KM7:TR?= NEDZeoRUSU6JRWK=
KG-1 NYnhfnRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfURXBKSzVyPUS3PE41PCEQvF2= MUXTRW5ITVJ?
LB771-HNC M4nRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7WV5dmUUN3ME20PFIvOjN{IN88US=> MUnTRW5ITVJ?
ACN NIf0TlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTR7Mz61PVkh|ryP NXLFfVdtW0GQR1XS
KM12 NIDnNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nNcWlEPTB;NEm2MlU5QSEQvF2= M2HRVXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble
In vivo Add solvents individually and in order:
10% DMSO+30% PEG 300+5% Tween 80+ddH2O
1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID